LEADERSHIP, PLANNING AND EVALUATION ABSTRACT Under strong new leadership from the UCLA Jonsson Comprehensive Cancer Center (JCCC) Director, Michael Teitell, MD, PhD (CMINT), a fresh, thorough, and prioritized JCCC strategic plan details a practical Center mission, to accelerate discoveries that prevent and cure cancer. A new JCCC leadership team infused enthusiasm into a Center culture that strives to eradicate cancer in LAC, the nation, and the world through impactful research as an aspirational vision. Driving mission success is a series of exciting and achievable goals for the next five-year project period and beyond. The JCCC 2019 ? 2023 Strategic Plan maps out a new governance structure, increased institutional support that includes participation in a pending centralized funds distribution mechanism, research priorities, patient-centered care initiatives, and addresses all 2013 CCSG study section comments. Significant enthusiasm emanates from increased organizational and financial commitments by new leaders in UCLA Health Sciences and an unprecedented organizational structure that elevates the JCCC role in fully integrating cancer research and clinical care at UCLA. This governance structure provides the infrastructure to support innovative and impactful basic, translational, clinical, and population science research, with strengthened community engagement to serve, and benefit from, a diverse Los Angeles County (LAC) JCCC catchment area. Adaptability helps the JCCC achieve its ambitious mission with continuous evaluation and planning activities, periodic evaluations by a reformulated External Advisory Board (EAB), focused ad-hoc reviews from consultants, and frequent opportunities for input from the breadth of the JCCC membership. Working with Teitell to drive forward Center progress is a 12-member senior leadership team, with each member having defined areas of expertise, oversight, and responsibility. JCCC leadership, planning, and evaluation occurs through four independent but related specific aims.
Aim 1 is to plan, set, and implement JCCC scientific goals and mission through the Strategic Plan, with ongoing evaluation of progress and corrective actions, to maximize basic, translational, clinical, and population research, emphasizing LAC catchment area needs.
Aim 2 is to enlist the JCCC EAB and ad-hoc experts to evaluate progress and identify growth opportunities that enhance cancer research productivity, education, training, and mentoring, and community outreach and engagement activities.
Aim 3 is to guide and foster impactful JCCC collaborative and transdisciplinary research through prioritized resource allocation.
Aim 4 is to facilitate Center-wide communications amongst Senior Leaders, Program Directors, Shared Resource Directors, members, trainees, and staff to guide the development and growth of the JCCC. With the vision of a new Director, there is excitement to build on historic strengths of the JCCC with a fresh focus on patient-centered integration of research, education/training, clinical care, and community engagement in the uniquely diverse setting of LAC. With this inflection point in the Center?s strategic trajectory, the JCCC of the near future will have added new heights to its very strong and impactful foundation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016042-44
Application #
9936727
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Black, David S; Cole, Steve W; Christodoulou, Georgia et al. (2018) Genomic mechanisms of fatigue in survivors of colorectal cancer. Cancer 124:2637-2644
Walser, Tonya C; Jing, Zhe; Tran, Linh M et al. (2018) Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Res 78:1986-1999
Chua, Bernadette Anne; Ngo, Jamie Ann; Situ, Kathy et al. (2018) Protein S and Gas6 induce efferocytosis of HIV-1-infected cells. Virology 515:176-190
Stanton, Annette L; Wiley, Joshua F; Krull, Jennifer L et al. (2018) Cancer-related coping processes as predictors of depressive symptoms, trajectories, and episodes. J Consult Clin Psychol 86:820-830
Glenn, Beth A; Hamilton, Ann S; Nonzee, Narissa J et al. (2018) Obesity, physical activity, and dietary behaviors in an ethnically-diverse sample of cancer survivors with early onset disease. J Psychosoc Oncol 36:418-436
Tsai, Wen-Ting K; Wu, Anna M (2018) Aligning physics and physiology: Engineering antibodies for radionuclide delivery. J Labelled Comp Radiopharm 61:693-714
Lisova, Ksenia; Sergeev, Maxim; Evans-Axelsson, Susan et al. (2018) Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors. Nucl Med Biol 61:36-44
Chang, Yu-Ling; Rossetti, Maura; Vlamakis, Hera et al. (2018) A screen of Crohn's disease-associated microbial metabolites identifies ascorbate as a novel metabolic inhibitor of activated human T cells. Mucosal Immunol :
Jia, Qingmei; Bowen, Richard; Dillon, Barbara Jane et al. (2018) Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia. Sci Rep 8:7009
Kiertscher, Sylvia M; Gangalum, Pallavi R; Ibrahim, Grace et al. (2018) A Prospective Study of Humoral and Cellular Immune Responses to Hepatitis B Vaccination in Habitual Marijuana Smokers. J Neuroimmune Pharmacol 13:219-229

Showing the most recent 10 out of 767 publications